Despite the recent flurry of gene therapy deals there is still a fairly extensive list of affordable companies out there.
An analysis of company disclosures reveals a sharp rise in US FDA-imposed halts on clinical work involving gene therapies.
The Japanese group has seen potential in Audentes' manufacturing capabilities as well as its pipeline.
Biolinerx’s BL-8040 needs to show improved responses in pancreatic cancer while investors will get a first look at Homology's HMI-102, a gene therapy for…
At 90 days data from Krystal Biotech’s epidermolysis bullosa trial looked good. At 120 days there has been some backsliding.
Zolgensma’s impressive early sales figures spur hopes that gene therapy could finally be coming of age.
Instead of tinkering with early-stage genome editing deals like this week's agreement with Bluebird, Novo Nordisk should make a decisive move in haemophilia.
Novo Nordisk took an early step towards genome editing with yesterday’s Bluebird tie-up, and isn’t ruling out a move into conventional gene therapies.
Tocagen’s Toca-5 trial has survived two interim reviews, and faces final readout by the end of this year.